Skip to main content

House Bill

H.R. 4881

119th Congress

SWIFT VOTE Act

In Committee
Introduced:Aug 8, 2025

Primary Sponsor

Robert J. Wittman

Robert J. Wittman

Representative

Republican
VA-1

Cosponsors

1

Quick Stats

Policy Area

Health

Summary

The SWIFT VOTE Act aims to reduce out-of-pocket costs for Medicare beneficiaries who need prescription drugs. It would limit the amount they have to pay for drugs to the average net price or the cash price, whichever is lower, during the coverage gap phase of their drug plan.

Latest Action

Referred to the Subcommittee on Health.

SponsorRobert J. Wittman (R-VA)
Introduced8/8/2025
StatusReferred to the House Committee on House Administration.
ChamberHouse
Data from Congress.gov

See this page through your district lens

Enter ZIP to personalize representatives and vote context.

Stay on top of this issue

Subscribe for weekly bill and representative updates.

Vote Prediction

SWIFT VOTE Act

The SWIFT VOTE Act aims to reduce out-of-pocket costs for Medicare beneficiaries who need prescription drugs. It would limit the amount they have to pay for drugs to the average net price or the cash price, whichever is lower, during the coverage gap phase of

Community Breakdown

Pass

0%

Fail

0%

0 predictions

The SWIFT VOTE Act aims to reduce out-of-pocket costs for Medicare beneficiaries who need prescription drugs. It would limit the amount they have to pay for drugs to the average net price or the cash price, whichever is lower, during the coverage gap phase of their drug plan.

Bill Number
4881
Sponsor
Robert J. Wittman (R-VA)
Introduced
8/8/2025
Status
Referred to the House Committee on House Administration.
Policy Area
Health

Data from Congress.gov

AI-generated summary

Fact Sheet

Title
SWIFT VOTE Act
Bill Number
4881
Sponsor
Robert J. Wittman (R-VA)
Status
Referred to the House Committee on House Administration.
Introduced
8/8/2025
Summary
The SWIFT VOTE Act aims to reduce out-of-pocket costs for Medicare beneficiaries who need prescription drugs. It would limit the amount they have to pay for drugs to the average net price or the cash price, whichever is lower, during the coverage gap phase of their drug plan.

Data from Congress.gov

Public Opinions

Community submissions related to this bill.

Share your opinion

No public opinions yet. Be the first to submit one for this bill.